Technology Bundle ID: TAB-2772

Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy

Request More Info
Licensing Contact:
Primary Inventors: 
Frederick Quinn (CDC)
Co-Inventors: 
Kristin Birkness (CDC), Manon Deslauriers (CDC), Peter King (CDC)
Development Stage: 
Prototype
Development Status: 
  • In vitro data available
  • Prototype
Institute or Center: 
CDC

CDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and in vitro candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic in situ granuloma formation in a controllable in vitro environment. This technology would be broadly useful for investigations into the numerous facets of early granuloma host-pathogen interaction, ultimately leading to improved prevention, intervention, and treatment strategies.

Applications:
  • In vitro modeling system
  • Basic research into tuberculosis-host interactions
  • Drug candidate screening
Advantages:
  • Low-cost alternative for modeling mycobacterial infections within complex tissue systems
  • Allows researchers to examine early-stage granuloma formation in a highly controllable, human-based modeling system
  • Cost-effective screening of potential therapeutic compounds and/or phenotypically-interesting mycobacteria

Patents

PCT Application PCT/US2002/000309
Filed on 2002-01-07
US Application 60/260,348
Filed on 2001-01-08
US Pat 7,105,170

Issued 2006-09-12

Various international patents issued or pending

Publications

Birkness KA, et al.
PMID 17199112

Updated

Feb 7, 2014

Data Source: 
tts